Company intelligence / Profile preview

Apeliotus Technologies

Atlanta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Apeliotus Technologies was a medical device company specializing in the early detection and monitoring of retinal diseases, specifically age-related macular degeneration (AMD). The company developed the AdaptDx, a non-invasive dark adaptometer that measures the time it takes for a patient's vision to adjust from light to dark. This measurement, known as the Rod Intercept (RI), serves as a highly sensitive functional biomarker for early-stage AMD, often detecting the disease years before clinical signs are visible. The company's technology was later acquired and commercialized by MacuLogix, becoming a standard tool in ophthalmic diagnostics.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Apeliotus Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apeliotus Technologies.

Explore the full profile